n(g),n(g')-dimethyl-l-arginine has been researched along with Diabetes Mellitus, Type 2 in 92 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a biomarker and mediator of cardiovascular disease in patients with impaired glucose tolerance (IGT) or diabetes mellitus (DM)." | 9.17 | Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. ( Imaizumi, T; Mizoguchi, M; Tahara, A; Tahara, N; Yamagishi, S, 2013) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 6.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| "Both hypertension and type 2 diabetes mellitus are common and there are no reliable markers either to predict their development or complications." | 6.47 | L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes. ( Dain, A; Das, UN; Eynard, AR; Repossi, G, 2011) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a biomarker and mediator of cardiovascular disease in patients with impaired glucose tolerance (IGT) or diabetes mellitus (DM)." | 5.17 | Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. ( Imaizumi, T; Mizoguchi, M; Tahara, A; Tahara, N; Yamagishi, S, 2013) |
| "In patients with T2D, hypertension and overt nephropathy, the renoprotection afforded by telmisartan and valsartan appears similar, and the study was unable to show any effect beyond that due to blood pressure control." | 5.13 | Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. ( Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C, 2008) |
| "Nutritional factors such as magnesium, folic acid, vitamins B12 and B6, L-arginine, and polyunsaturated fatty acids (PUFAs) appear to be significantly beneficial for patients with coronary artery disease (CAD), and in the prevention and arresting the progression of HF and cardiac arrhythmias." | 4.91 | Nutritional factors in the prevention and management of coronary artery disease and heart failure. ( Das, UN, 2015) |
| " We employed a case-cohort design, nested within the PREDIMED trial, to examine six plasma metabolites (arginine, citrulline, ornithine, asymmetric dimethylarginine [ADMA], symmetric dimethylarginine [SDMA] and N-monomethyl-l-arginine [NMMA]) among 892 individuals (251 cases) for associations with incident T2D and insulin resistance." | 3.91 | Changes in arginine are inversely associated with type 2 diabetes: A case-cohort study in the PREDIMED trial. ( Arós, F; Bullo, M; Clish, C; Cofán, M; Corella, D; Dennis, C; Estruch, R; Fitó, M; Guasch-Ferré, M; Gutiérrez-Bedmar, M; Hu, FB; Lapetra, J; Liang, L; Martínez-González, MA; Papandreou, C; Razquin, C; Romaguera, D; Ros, E; Ruiz-Canela, M; Salas-Salvadó, J; Serra-Majem, L; Sorlí, JV; Toledo, E; Wang, DD; Yu, E, 2019) |
| "Elevated levels of circulating asymmetric and symmetric dimethylarginines (ADMA and SDMA) predict and potentially contribute to end organ damage in cardiovascular diseases." | 3.83 | Diabetes-linked transcription factor HNF4α regulates metabolism of endogenous methylarginines and β-aminoisobutyric acid by controlling expression of alanine-glyoxylate aminotransferase 2. ( Bode-Böger, SM; Bornstein, SR; Brilloff, S; Brocker, C; Burdin, DV; Demyanov, AV; Gonzalez, F; Jarzebska, N; Kolobov, AA; Maas, R; Martens-Lobenhoffer, J; Mieth, M; Rodionov, RN; Samusik, N; Soshnev, AA; Weiss, N, 2016) |
| "Elevated plasma levels of asymmetric dimethylarginine (ADMA) has been reported to be associated with insulin resistance and micro/macrovascular diabetic complications, and may predict cardiovascular events in type 2 diabetic patients." | 3.77 | The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. ( Chung, MY; Hsu, CP; Lin, MW; Lin, SJ; Lu, TM, 2011) |
| "Although asymmetric dimethylarginine (ADMA) is known to be involved in the developing process of cardiovascular diseases (CVD), little is known about the effects of ADMA on atherosclerosis in Asian patients with diabetes, who have the racial feature of lower body mass index (BMI) and decreased capacity of insulin secretion and sensitivity." | 3.77 | Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus. ( Kanazawa, I; Nabika, T; Notsu, Y; Sugimoto, T; Yamaguchi, T; Yano, S, 2011) |
| " However, it is unknown whether excess weight, insulin resistance, and asymmetric dimethylarginine (ADMA)--an endogenous nitric oxide (NO) synthase inhibitor--also contribute to the vascular changes observed in these patients." | 3.74 | Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes. ( Kautzky-Willer, A; Langenberger, H; Mittermayer, F; Pacini, G; Pleiner, J; Schaller, G; Tura, A; Winzer, C; Wolzt, M, 2007) |
| "In patients with type 2 diabetes (T2D) sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve glycaemic control as well as cardiovascular and renal outcomes." | 3.11 | Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. ( Bosch, A; Fromm, MF; Gemeinhardt, A; Gessner, A; Kannenkeril, D; Maas, R; Mayr, A; Schmieder, RE; Staerk, C, 2022) |
| "Patients with type 2 diabetes and diabetic microvascular complications have significantly elevated levels of Asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS)." | 3.01 | Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. ( Guo, X; Jin, W; Xing, Y, 2023) |
| "Aims Patients with type 2 diabetes mellitus (T2DM) are prone to cardiovascular disease (CVD) due to inflammation process and oxidative stress." | 2.87 | Asymmetric dimethylarginine and soluble inter-cellular adhesion molecule-1 serum levels alteration following ginger supplementation in patients with type 2 diabetes: a randomized double-blind, placebo-controlled clinical trial. ( Abdollahi, M; Effatpanah, M; Hashemi, R; Khorshidi, M; Kord Varkane, H; Makhdoomi Arzati, M; Mohammadzadeh Honarvar, N; Saedisomeolia, A; Yekaninejad, MS; Zarezadeh, M, 2018) |
| "Trelagliptin treatment showed no significant changes in FMD (2." | 2.82 | Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. ( Betou, K; Fujiwara, R; Ida, S; Imataka, K; Ishihara, Y; Kaneko, R; Kobayashi, C; Monguchi, K; Murata, K; Takahashi, H; Uchida, A, 2016) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 2.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| "Forty-four patients with Type 2 diabetes were included in the study." | 2.77 | Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. ( Anders, S; Forst, T; Michelson, G; Mitry, M; Pfützner, A; Ratter, F; Weber, MM; Wilhelm, B, 2012) |
| "Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus." | 2.75 | Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. ( Averna, M; Ciabattoni, G; Consoli, A; Davì, G; Di Fulvio, P; Formoso, G; Ganci, A; Lattanzio, S; Lauro, R; Miccoli, R; Patrono, C; Pulizzi, N; Santilli, F; Sbraccia, P, 2010) |
| "In study II, 41 patients with type 2 diabetes and mild hyperhomocysteinaemia were analysed after 6 months treatment with 5 mg of folic acid or placebo." | 2.72 | No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk. ( Brouwer, CB; Rauwerda, JA; Smulders, YM; Spoelstra-de Man, AM; Stehouwer, CD; Teerlink, T, 2006) |
| "Fifty patients with type 2 diabetes mellitus were studied at baseline and 5 hours after ingestion of a high-fat meal." | 2.69 | Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. ( Berglund, L; Bryant, TA; Cannon, PJ; Chen, NT; Di Tullio, MR; Donis, JA; Fard, A; Ginsberg, HN; Homma, S; Ramasamy, R; Sciacca, R; Torres-Tamayo, M; Tuck, CH; Wu, HD, 2000) |
| "Both hypertension and type 2 diabetes mellitus are common and there are no reliable markers either to predict their development or complications." | 2.47 | L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes. ( Dain, A; Das, UN; Eynard, AR; Repossi, G, 2011) |
| "Dimethylarginine dimethylaminohydrolase (DDAH) 1 maintains the bioavailability of nitric oxide by degrading asymmetric dimethylarginine (ADMA)." | 1.72 | The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy. ( Deng, Z; Hu, C; Jia, W; Wang, S; Yan, D; Zhang, H; Zhang, R; Zheng, X, 2022) |
| "Patients with type 2 diabetes represent 50% of all sudden cardiac deaths." | 1.62 | Lack of evidence of the correlation between plasma Asymmetrical Dimethylarginine correlation and IMT in type 2 diabetic patients with chronic vascular complication. ( Adamiec, R; Dumas, I; Fiodorenko-Dumas, Z; Małecki, R; Paprocka-Borowicz, M; Rabczynski, M, 2021) |
| "Type 2 diabetes is related to higher intraplatelet concentration of asymmetric dimethylarginine (ADMA), which may result in impaired platelet-derived nitric oxide synthesis and subsequent increased platelet activity, as assessed by the ADP-induced aggregation." | 1.56 | Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus. ( Doroszko, A; Fortuna, P; Gajecki, D; Gawryś, J; Gawryś, K; Leśniewska, J; Majda, F; Mlynarz, P; Szahidewicz-Krupska, E; Wiśniewski, J, 2020) |
| "HIV infection and type 2 diabetes are associated with altered gut microbiota, chronic inflammation, and increased cardiovascular risk." | 1.48 | Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction. ( Aukrust, P; Gaardbo, JC; Gelpi, M; Gerstoft, J; Hoel, H; Holm, K; Hov, JR; Hove-Skovsgaard, M; Kummen, M; Nielsen, SD; Nwosu, F; Rudi, K; Seljeflot, I; Trøseid, M; Ueland, PM; Ullum, H; Valeur, J, 2018) |
| "Albuminuria was calculated using urinary albumin and creatinine ratio (UACR)." | 1.46 | Association of circulatory asymmetric dimethylarginine (ADMA) with diabetic nephropathy in Asian Indians and its causative role in renal cell injury. ( Balasubramanyam, M; Jayachandran, I; Manickam, N; Mohan, V; Paramasivam, P; Subramanian, SC; Sundararajan, S; Venkatesan, B, 2017) |
| "Patients with type 2 diabetes mellitus were divided into three groups according to daily albumin excretion: normoalbuminuria, microalbuminuria and macroalbuminuria (n=30 in each)." | 1.42 | The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes. ( Aycan-Ustyol, E; Bekpinar, S; Dinccag, N; Gurdol, F; Unlucerci, Y; Yenidunya, G, 2015) |
| "Seventy patients with type 2 diabetes mellitus and 11 healthy subjects were assessed concerning urine albumin: creatinine ratio, plasma and urinary advanced glycation end-products, plasma asymmetric dimethyl-arginine, serum cystatin C, intima-media thickness in the common carotid arteries, the pulsatility index, the resistance index in the internal carotid arteries and the middle cerebral arteries, the cerebrovascular reactivity through the breath-holding test." | 1.42 | Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study. ( Bob, F; Dumitrascu, V; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Jianu, DC; Petrica, L; Petrica, M; Popescu, R; Ursoniu, S; Velciov, S; Vlad, A; Vlad, D, 2015) |
| "Insulin sensitivity was impaired only in T2DM." | 1.39 | Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo. ( Artusi, C; Cecchet, D; Millioni, R; Plebani, M; Puricelli, L; Tessari, P; Vedovato, M; Vettore, M, 2013) |
| "Patients with type 2 diabetes had significantly higher serum HSP70 (0." | 1.38 | The dual behavior of heat shock protein 70 and asymmetric dimethylarginine in relation to serum CRP levels in type 2 diabetes. ( Asgarani, F; Bathaie, SZ; Esteghamati, A; Ghazizadeh, Z; Khalilzadeh, O; Morteza, A; Nakhjavani, M, 2012) |
| "Carotid atherosclerosis was determined by ultrasonographically evaluated intima- media thickness (IMT) and plaque score." | 1.38 | Asymmetric dimethylarginine and carotid atherosclerosis in Type 2 diabetes mellitus. ( Chi, Y; Shao, Y; Wang, X; Wang, Y; Xia, W, 2012) |
| "A total of 341 type 1 and type 2 diabetes patients with variable degree of kidney disease were included at baseline." | 1.38 | ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis. ( Bartáková, V; Bělobrádková, J; Jurajda, M; Kaňková, K; Klepárník, M; Krusová, D; Kuricová, K; Malúšková, D; Mužík, J; Olšovský, J; Pácal, L; Pavlík, T; Rehořová, J; Stěpánková, S; Svojanovský, J; Tanhäuserová, V; Tomandl, J, 2012) |
| "The method was successfully applied to type 2 diabetes mellitus (T2DM) study." | 1.37 | Quantitation of L-arginine and asymmetric dimethylarginine in human plasma by LC-selective ion mode-MS for Type 2 diabetes mellitus study. ( Chen, B; Ji, X; Liang, Y; Wang, Y; Yi, L; Zhang, P; Zhou, Z, 2011) |
| "In India, number of people with type 2 Diabetes Mellitus (DM) would be 87 million by the year 2030." | 1.37 | Changes of skin temperature of parts of the body and serum asymmetric dimethylarginine (ADMA) in type-2 diabetes mellitus Indian patients. ( Anburajan, M; Bidyarasmi, S; Menaka, M; Raj, B; Sivanandam, S; Venkatraman, B, 2011) |
| "Patients with type 2 diabetes (T2DM) have higher incidence of macrovascular disease than the general population." | 1.33 | Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. ( Hofer, M; Krugluger, W; Krzyzanowska, K; Mittermayer, F; Schernthaner, G; Schnack, C; Wolzt, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (26.09) | 29.6817 |
| 2010's | 58 (63.04) | 24.3611 |
| 2020's | 10 (10.87) | 2.80 |
| Authors | Studies |
|---|---|
| Gessner, A | 1 |
| Gemeinhardt, A | 1 |
| Bosch, A | 1 |
| Kannenkeril, D | 1 |
| Staerk, C | 1 |
| Mayr, A | 1 |
| Fromm, MF | 1 |
| Schmieder, RE | 1 |
| Maas, R | 3 |
| Fang, WJ | 2 |
| Li, XM | 1 |
| Zhou, XK | 1 |
| Xiong, Y | 3 |
| Wang, S | 3 |
| Deng, Z | 3 |
| Zhang, H | 3 |
| Zhang, R | 3 |
| Yan, D | 3 |
| Zheng, X | 3 |
| Jia, W | 3 |
| Hu, C | 3 |
| Guo, X | 1 |
| Xing, Y | 1 |
| Jin, W | 1 |
| Leffler, KE | 1 |
| Abdel-Rahman, AA | 1 |
| Gać, P | 1 |
| Poręba, M | 1 |
| Jurdziak, M | 1 |
| Trzmielewska, E | 1 |
| Gocławska, K | 1 |
| Derkacz, A | 1 |
| Mazur, G | 1 |
| Szuba, A | 1 |
| Poręba, R | 1 |
| Wieczór, R | 1 |
| Wieczór, AM | 1 |
| Kulwas, A | 1 |
| Rość, D | 1 |
| Gawryś, J | 2 |
| Wiśniewski, J | 2 |
| Szahidewicz-Krupska, E | 2 |
| Gajecki, D | 2 |
| Leśniewska, J | 1 |
| Majda, F | 1 |
| Gawryś, K | 1 |
| Fortuna, P | 2 |
| Mlynarz, P | 1 |
| Doroszko, A | 2 |
| Fiodorenko-Dumas, Z | 2 |
| Dumas, I | 2 |
| Rabczynski, M | 1 |
| Małecki, R | 1 |
| Adamiec, R | 2 |
| Paprocka-Borowicz, M | 1 |
| Hove-Skovsgaard, M | 2 |
| Gaardbo, JC | 2 |
| Kolte, L | 1 |
| Winding, K | 1 |
| Seljeflot, I | 2 |
| Svardal, A | 1 |
| Berge, RK | 1 |
| Gerstoft, J | 2 |
| Ullum, H | 2 |
| Trøseid, M | 2 |
| Nielsen, SD | 2 |
| Jayachandran, I | 1 |
| Sundararajan, S | 1 |
| Paramasivam, P | 1 |
| Venkatesan, B | 1 |
| Subramanian, SC | 1 |
| Balasubramanyam, M | 1 |
| Mohan, V | 1 |
| Manickam, N | 1 |
| Mastej, K | 1 |
| Triches, CB | 2 |
| Quinto, M | 1 |
| Mayer, S | 2 |
| Batista, M | 1 |
| Zanella, MT | 2 |
| Quinto, BMR | 1 |
| Batista, MC | 1 |
| Hoel, H | 1 |
| Hov, JR | 1 |
| Holm, K | 1 |
| Kummen, M | 1 |
| Rudi, K | 1 |
| Nwosu, F | 1 |
| Valeur, J | 1 |
| Gelpi, M | 1 |
| Ueland, PM | 1 |
| Aukrust, P | 2 |
| Zarezadeh, M | 1 |
| Saedisomeolia, A | 1 |
| Khorshidi, M | 1 |
| Kord Varkane, H | 1 |
| Makhdoomi Arzati, M | 1 |
| Abdollahi, M | 1 |
| Yekaninejad, MS | 1 |
| Hashemi, R | 1 |
| Effatpanah, M | 1 |
| Mohammadzadeh Honarvar, N | 1 |
| Yu, E | 1 |
| Ruiz-Canela, M | 1 |
| Razquin, C | 1 |
| Guasch-Ferré, M | 1 |
| Toledo, E | 1 |
| Wang, DD | 1 |
| Papandreou, C | 1 |
| Dennis, C | 1 |
| Clish, C | 1 |
| Liang, L | 1 |
| Bullo, M | 1 |
| Corella, D | 1 |
| Fitó, M | 1 |
| Gutiérrez-Bedmar, M | 1 |
| Lapetra, J | 1 |
| Estruch, R | 1 |
| Ros, E | 1 |
| Cofán, M | 1 |
| Arós, F | 1 |
| Romaguera, D | 1 |
| Serra-Majem, L | 1 |
| Sorlí, JV | 1 |
| Salas-Salvadó, J | 1 |
| Hu, FB | 1 |
| Martínez-González, MA | 1 |
| Yokoro, M | 1 |
| Minami, M | 1 |
| Okada, S | 1 |
| Yano, M | 1 |
| Otaki, N | 1 |
| Ikeda, H | 1 |
| Fukuo, K | 1 |
| Tahara, N | 2 |
| Kojima, R | 1 |
| Yoshida, R | 1 |
| Bekki, M | 1 |
| Sugiyama, Y | 1 |
| Tahara, A | 2 |
| Maeda, S | 1 |
| Honda, A | 1 |
| Igata, S | 1 |
| Nakamura, T | 1 |
| Sun, J | 1 |
| Matsui, T | 2 |
| Fukumoto, Y | 1 |
| Yamagishi, SI | 1 |
| Tessari, P | 1 |
| Cecchet, D | 1 |
| Artusi, C | 1 |
| Vettore, M | 1 |
| Millioni, R | 1 |
| Plebani, M | 1 |
| Puricelli, L | 1 |
| Vedovato, M | 1 |
| Taner, A | 2 |
| Unlu, A | 2 |
| Kayrak, M | 2 |
| Tekinalp, M | 2 |
| Ayhan, SS | 1 |
| Arıbaş, A | 2 |
| Erdem, SS | 1 |
| Surdacki, A | 2 |
| Kruszelnicka, O | 2 |
| Rakowski, T | 1 |
| Jaźwińska-Kozuba, A | 1 |
| Dubiel, JS | 1 |
| Yamagishi, S | 1 |
| Mizoguchi, M | 1 |
| Imaizumi, T | 1 |
| Bøtker, HE | 1 |
| Møller, N | 1 |
| Anderssohn, M | 1 |
| McLachlan, S | 1 |
| Lüneburg, N | 1 |
| Robertson, C | 1 |
| Schwedhelm, E | 3 |
| Williamson, RM | 1 |
| Strachan, MW | 1 |
| Ajjan, R | 1 |
| Grant, PJ | 1 |
| Böger, RH | 4 |
| Price, JF | 1 |
| Začiragić, A | 1 |
| Huskić, J | 1 |
| Mulabegović, N | 1 |
| Avdagić, N | 1 |
| Valjevac, A | 1 |
| Hasić, S | 1 |
| Jadrić, R | 1 |
| Cakirca, M | 1 |
| Karatoprak, C | 1 |
| Zorlu, M | 1 |
| Kiskac, M | 1 |
| Kanat, M | 1 |
| Cikrikcioglu, MA | 1 |
| Soysal, P | 1 |
| Hursitoglu, M | 1 |
| Camli, AA | 1 |
| Erkoc, R | 1 |
| Abdul-Ghani, M | 1 |
| Celik, M | 1 |
| Cerrah, S | 1 |
| Arabul, M | 1 |
| Akalin, A | 1 |
| Leng, YP | 1 |
| Qiu, N | 1 |
| Zhang, M | 1 |
| He, ZM | 1 |
| Lattanzio, S | 2 |
| Santilli, F | 3 |
| Liani, R | 1 |
| Vazzana, N | 1 |
| Ueland, T | 1 |
| Di Fulvio, P | 2 |
| Formoso, G | 3 |
| Consoli, A | 3 |
| Davì, G | 3 |
| Petrica, L | 1 |
| Vlad, A | 1 |
| Gluhovschi, G | 1 |
| Gadalean, F | 1 |
| Dumitrascu, V | 1 |
| Vlad, D | 1 |
| Popescu, R | 1 |
| Velciov, S | 1 |
| Gluhovschi, C | 1 |
| Bob, F | 1 |
| Ursoniu, S | 1 |
| Petrica, M | 1 |
| Jianu, DC | 1 |
| Das, UN | 2 |
| Yuan, Q | 1 |
| Hu, CP | 1 |
| Gong, ZC | 1 |
| Bai, YP | 1 |
| Liu, SY | 1 |
| Li, YJ | 1 |
| Jiang, JL | 1 |
| Chyrchel, B | 1 |
| Golay, A | 1 |
| Takaya, J | 1 |
| Tanabe, Y | 1 |
| Kuroyanagi, Y | 1 |
| Kaneko, K | 1 |
| Akilli, H | 1 |
| Alibasic, H | 1 |
| Yildirim, S | 1 |
| Gunduz, M | 1 |
| Jing, Z | 2 |
| Kuang, L | 2 |
| Liu, N | 2 |
| Yang, J | 2 |
| Hosseinzadeh-Attar, M | 1 |
| Kolahdouz Mohammadi, R | 1 |
| Eshraghian, M | 1 |
| Nakhjavani, M | 3 |
| Khorrami, E | 1 |
| Ebadi, M | 1 |
| Esteghamati, A | 3 |
| Bekpinar, S | 1 |
| Yenidunya, G | 1 |
| Gurdol, F | 1 |
| Unlucerci, Y | 1 |
| Aycan-Ustyol, E | 1 |
| Dinccag, N | 1 |
| Wang, Y | 3 |
| He, J | 1 |
| Sun, Z | 1 |
| Ganz, T | 1 |
| Wainstein, J | 1 |
| Gilad, S | 1 |
| Limor, R | 1 |
| Boaz, M | 1 |
| Stern, N | 1 |
| Tariq, K | 1 |
| Khan, MA | 1 |
| Burdin, DV | 1 |
| Kolobov, AA | 1 |
| Brocker, C | 1 |
| Soshnev, AA | 1 |
| Samusik, N | 1 |
| Demyanov, AV | 1 |
| Brilloff, S | 1 |
| Jarzebska, N | 1 |
| Martens-Lobenhoffer, J | 2 |
| Mieth, M | 1 |
| Bornstein, SR | 1 |
| Bode-Böger, SM | 2 |
| Gonzalez, F | 1 |
| Weiss, N | 1 |
| Rodionov, RN | 1 |
| Ida, S | 1 |
| Murata, K | 1 |
| Betou, K | 1 |
| Kobayashi, C | 1 |
| Ishihara, Y | 1 |
| Imataka, K | 1 |
| Uchida, A | 1 |
| Monguchi, K | 1 |
| Kaneko, R | 1 |
| Fujiwara, R | 1 |
| Takahashi, H | 1 |
| Vida, G | 1 |
| Sulyok, E | 1 |
| Lakatos, O | 1 |
| Ertl, T | 1 |
| Hanai, K | 1 |
| Babazono, T | 1 |
| Nyumura, I | 1 |
| Toya, K | 1 |
| Tanaka, N | 1 |
| Tanaka, M | 1 |
| Ishii, A | 1 |
| Iwamoto, Y | 1 |
| Karakurt, F | 1 |
| Carlioglu, A | 1 |
| Koktener, A | 1 |
| Ozbek, M | 1 |
| Kaya, A | 1 |
| Uyar, ME | 1 |
| Kasapoglu, B | 1 |
| Ilhan, A | 1 |
| Forst, T | 2 |
| Pfützner, A | 2 |
| Flacke, F | 1 |
| Krasner, A | 1 |
| Hohberg, C | 1 |
| Tarakci, E | 1 |
| Pichotta, P | 1 |
| Forst, S | 1 |
| Steiner, S | 1 |
| Mittermayer, F | 4 |
| Pleiner, J | 2 |
| Francesconi, M | 1 |
| Wolzt, M | 4 |
| Sbraccia, P | 1 |
| Averna, M | 1 |
| Miccoli, R | 1 |
| Ganci, A | 1 |
| Pulizzi, N | 1 |
| Ciabattoni, G | 2 |
| Lauro, R | 1 |
| Patrono, C | 1 |
| Soro-Paavonen, A | 1 |
| Zhang, WZ | 1 |
| Venardos, K | 1 |
| Coughlan, MT | 1 |
| Harris, E | 1 |
| Tong, DC | 1 |
| Brasacchio, D | 1 |
| Paavonen, K | 1 |
| Chin-Dusting, J | 1 |
| Cooper, ME | 1 |
| Kaye, D | 1 |
| Thomas, MC | 1 |
| Forbes, JM | 1 |
| Abhary, S | 1 |
| Burdon, KP | 1 |
| Kuot, A | 1 |
| Javadiyan, S | 1 |
| Whiting, MJ | 1 |
| Kasmeridis, N | 1 |
| Petrovsky, N | 1 |
| Craig, JE | 1 |
| Karimi-Jafari, H | 1 |
| Khalilzadeh, O | 2 |
| Asgarani, F | 2 |
| Ghadiri-Anari, A | 1 |
| Kanazawa, I | 2 |
| Yano, S | 2 |
| Yamaguchi, T | 2 |
| Notsu, Y | 2 |
| Nabika, T | 2 |
| Sugimoto, T | 2 |
| Sonmez, A | 1 |
| Haymana, C | 1 |
| Tapan, S | 1 |
| Safer, U | 1 |
| Celebi, G | 1 |
| Ozturk, O | 1 |
| Genc, H | 1 |
| Dogru, T | 1 |
| Tasci, I | 1 |
| Erdem, G | 1 |
| Taslipinar, A | 1 |
| Aydogdu, A | 1 |
| Yilmaz, MI | 1 |
| Kurt, I | 1 |
| Kutlu, M | 1 |
| Siervo, M | 1 |
| Corander, M | 1 |
| Stranges, S | 1 |
| Bluck, L | 1 |
| Repossi, G | 1 |
| Dain, A | 1 |
| Eynard, AR | 1 |
| Lu, TM | 1 |
| Lin, SJ | 1 |
| Lin, MW | 1 |
| Hsu, CP | 1 |
| Chung, MY | 1 |
| King, DE | 1 |
| Player, M | 1 |
| Everett, CJ | 1 |
| Yi, L | 1 |
| Zhang, P | 1 |
| Ji, X | 1 |
| Liang, Y | 1 |
| Zhou, Z | 1 |
| Chen, B | 1 |
| El-Mesallamy, HO | 1 |
| Hamdy, NM | 1 |
| Ezzat, OA | 1 |
| Reda, AM | 1 |
| Anburajan, M | 1 |
| Sivanandam, S | 1 |
| Bidyarasmi, S | 1 |
| Venkatraman, B | 1 |
| Menaka, M | 1 |
| Raj, B | 1 |
| Michelson, G | 1 |
| Ratter, F | 1 |
| Weber, MM | 1 |
| Anders, S | 1 |
| Mitry, M | 1 |
| Wilhelm, B | 1 |
| Morteza, A | 1 |
| Ghazizadeh, Z | 1 |
| Bathaie, SZ | 1 |
| Akyel, A | 1 |
| Çengel, A | 1 |
| Tavil, Y | 1 |
| Şahinarslan, A | 1 |
| Topal, S | 1 |
| Yayla, Ç | 1 |
| Elbeğ, Ş | 1 |
| Boyaci, B | 1 |
| Arslan, M | 1 |
| Marra, M | 1 |
| Marchegiani, F | 1 |
| Ceriello, A | 1 |
| Sirolla, C | 1 |
| Boemi, M | 1 |
| Franceschi, C | 1 |
| Spazzafumo, L | 1 |
| Testa, I | 1 |
| Bonfigli, AR | 1 |
| Cucchi, M | 1 |
| Testa, R | 1 |
| Xia, W | 1 |
| Shao, Y | 1 |
| Wang, X | 1 |
| Chi, Y | 1 |
| Tanhäuserová, V | 1 |
| Tomandl, J | 1 |
| Pácal, L | 1 |
| Klepárník, M | 1 |
| Malúšková, D | 1 |
| Bartáková, V | 1 |
| Kuricová, K | 1 |
| Rehořová, J | 1 |
| Stěpánková, S | 1 |
| Svojanovský, J | 1 |
| Olšovský, J | 1 |
| Bělobrádková, J | 1 |
| Krusová, D | 1 |
| Jurajda, M | 1 |
| Mužík, J | 1 |
| Pavlík, T | 1 |
| Kaňková, K | 1 |
| Sciacqua, A | 1 |
| Grillo, N | 1 |
| Quero, M | 1 |
| Sesti, G | 1 |
| Perticone, F | 1 |
| Ito, A | 1 |
| Egashira, K | 1 |
| Narishige, T | 1 |
| Muramatsu, K | 1 |
| Takeshita, A | 1 |
| Päivä, H | 1 |
| Lehtimäki, T | 1 |
| Laakso, J | 1 |
| Ruokonen, I | 1 |
| Rantalaiho, V | 1 |
| Wirta, O | 1 |
| Pasternack, A | 1 |
| Laaksonen, R | 1 |
| Lei, M | 1 |
| Fu, S | 1 |
| Fu, Y | 1 |
| Kawata, T | 2 |
| Daimon, M | 2 |
| Hasegawa, R | 2 |
| Teramoto, K | 2 |
| Toyoda, T | 2 |
| Sekine, T | 2 |
| Yamamoto, K | 2 |
| Uchida, D | 2 |
| Himi, T | 2 |
| Yoshida, K | 2 |
| Komuro, I | 2 |
| Krzyzanowska, K | 2 |
| Krugluger, W | 1 |
| Schnack, C | 1 |
| Hofer, M | 1 |
| Schernthaner, G | 2 |
| Quispe-Bravo, S | 1 |
| Skamira, C | 1 |
| Yasuda, S | 1 |
| Miyazaki, S | 1 |
| Kanda, M | 1 |
| Goto, Y | 1 |
| Suzuki, M | 1 |
| Harano, Y | 1 |
| Nonogi, H | 1 |
| Spoelstra-de Man, AM | 1 |
| Teerlink, T | 1 |
| Brouwer, CB | 1 |
| Rauwerda, JA | 1 |
| Stehouwer, CD | 1 |
| Smulders, YM | 1 |
| Blardi, P | 1 |
| de Lalla, A | 1 |
| Pieragalli, D | 1 |
| De Franco, V | 1 |
| Meini, S | 1 |
| Ceccatelli, L | 1 |
| Auteri, A | 1 |
| Ding, H | 1 |
| Triggle, CR | 1 |
| Gao, HW | 1 |
| Xie, C | 1 |
| Wang, HN | 1 |
| Lin, YJ | 1 |
| Hong, TP | 1 |
| Boykin, JV | 1 |
| Baylis, C | 1 |
| Devangelio, E | 1 |
| Ferroni, P | 1 |
| Bucciarelli, L | 1 |
| Michetti, N | 1 |
| Clissa, C | 1 |
| Langenberger, H | 1 |
| Winzer, C | 1 |
| Schaller, G | 1 |
| Pacini, G | 1 |
| Kautzky-Willer, A | 1 |
| Tura, A | 1 |
| Galle, J | 1 |
| Pinnetti, S | 1 |
| Wanner, C | 1 |
| Fard, A | 1 |
| Tuck, CH | 1 |
| Donis, JA | 1 |
| Sciacca, R | 1 |
| Di Tullio, MR | 1 |
| Wu, HD | 1 |
| Bryant, TA | 1 |
| Chen, NT | 1 |
| Torres-Tamayo, M | 1 |
| Ramasamy, R | 1 |
| Berglund, L | 1 |
| Ginsberg, HN | 1 |
| Homma, S | 1 |
| Cannon, PJ | 1 |
| Abbasi, F | 2 |
| Asagmi, T | 1 |
| Cooke, JP | 2 |
| Lamendola, C | 2 |
| McLaughlin, T | 2 |
| Reaven, GM | 2 |
| Stuehlinger, M | 1 |
| Tsao, PS | 2 |
| Asagami, T | 1 |
| Stuelinger, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function[NCT02471963] | Phase 3 | 74 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Randomized, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content[NCT02383238] | Phase 3 | 59 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| The Effect of Dexamethasone Implant on Retinal Nerve Fiber and Optic Disc Morphology in Patients With Diabetic Maculopathy[NCT03927118] | 43 participants (Actual) | Observational | 2018-02-01 | Completed | |||
| Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus[NCT01208012] | Phase 4 | 44 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus[NCT01030952] | Phase 4 | 103 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients[NCT00928889] | Phase 4 | 160 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Glycemic Variability Predicts Endothelial Dysfunction[NCT01083043] | 28 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| Measurements of Endothelial Function by Means of Peripheral Arterial Tonometry in Diabetic Foot Ulcer Patients Undergoing Hyperbaric Oxygen Therapy.[NCT02221466] | 45 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The postprandial glucose area under the curve (AUC)was calculated using values from the 3 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.~0-4 hours AUC were calculated using trapezoid methods." (NCT01030952)
Timeframe: 3 weeks (end of study) minus baseline
| Intervention | millimoles hours per litre (mmol*hr/L) (Least Squares Mean) |
|---|---|
| Nateglinide | -9.20 |
| Acarbose | -9.92 |
GSA levels were to be determined by CGMS at 7:00~10:00 am in the 4-hour standardized meal test before treatment after overnight fasting for efficacy assessments (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | percent (Mean) |
|---|---|
| Nateglinide | -2.22 |
| Acarbose | -1.74 |
Incremental glucose peak (IGP) was the maximal incremental increase in blood glucose obtained at any point after meal (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | millimoles per litre (mmol/L) (Mean) |
|---|---|
| Nateglinide | -2.72 |
| Acarbose | -1.89 |
mean amplitude of glycaemic excursion (MAGE) is an average of the amplitudes of all glycemic excursions greater than a prespecified threshold size (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | mmol/l (Mean) |
|---|---|
| Nateglinide | 5.27 |
| Acarbose | 5.03 |
The 24 hour mean blood glucose (MBG) level was calculated as the mean of all the consecutive readings on baseline and end of study(3 weeks later) separately. (NCT01030952)
Timeframe: baseline and at 3 weeks (end of study)
| Intervention | millimoles per litre (mmol/l) (Mean) |
|---|---|
| Nateglinide | -1.16 |
| Acarbose | -0.78 |
The mean of the daily differences (MODD), calculated as the average absolute difference of paired glucose values during two successive 24 hour periods, was used to assess day-to-day glycaemic variability. (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | millimoles per litre (mmol/l) (Mean) |
|---|---|
| Nateglinide | -0.06 |
| Acarbose | -0.21 |
Measures/compares changes in percentage of hyperglycemia (>7.8mmol/l or 140 mg/dl) in glucose measurements in 24 hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values [100% * ((X-Y)/Y)] (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | percent of measurements (Mean) |
|---|---|
| Nateglinide | -50.83 |
| Acarbose | -33.82 |
Change in standard deviation (SD) from baseline of mean blood glucose (MBG) describes the range of blood glucose fluctuation over 24 hours. (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | mmol/l (Mean) |
|---|---|
| Nateglinide | -0.48 |
| Acarbose | -0.63 |
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT01030952)
Timeframe: baseline, end of study (3 weeks)
| Intervention | mmol*min/L (Mean) |
|---|---|
| Nateglinide | -1.16 |
| Acarbose | -0.78 |
Measures/compares changes in percentage of hypoglycemia(<3.9mmol/l or <70 mg/dl) in glucose measurements in 24hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values [100% * ((X-Y)/Y)] (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | percent of measurements (Mean) |
|---|---|
| Nateglinide | 0.82 |
| Acarbose | -0.57 |
Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 3. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value. (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | millimoles per litre (mmol/l) (Mean) | ||
|---|---|---|---|
| 0 minutes | 30 minutes | 120 minutes | |
| Acarbose | -0.02 | 0.01 | 0.00 |
| Nateglinide | 0.20 | 0.02 | 0.03 |
change in LDL-C at 0, 30 and 120 minutes (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | millimoles per litre (mmol/l) (Mean) | ||
|---|---|---|---|
| 0 minutes | 30 minutes | 120 minutes | |
| Acarbose | 0.064 | 0.09 | 0.13 |
| Nateglinide | -0.04 | -0.06 | -0.04 |
This outcome measure calculated the change in insulin levels between groups over time at 0, 30 then 120 minutes (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | (μU/ml) (Mean) | ||
|---|---|---|---|
| 0 minutes | 30 minutes | 120 minutes | |
| Acarbose | -0.21 | -6.64 | -16.24 |
| Nateglinide | 0.32 | 13.87 | 15.03 |
TG change in blood lipids level from baseline to endpoint (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | millimoles per litre (mmol/l) (Mean) | ||
|---|---|---|---|
| 0 minutes | 30 minutes | 120 minutes | |
| Acarbose | -0.48 | -0.39 | -0.47 |
| Nateglinide | -0.19 | -0.23 | -0.19 |
time to change in Total Cholesterol blood lipids level at 0, 30, 120 minutes (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)
| Intervention | millimoles per litre (mmol/l) (Mean) | ||
|---|---|---|---|
| 0 minutes | 30 minutes | 120 minutes | |
| Acarbose | -0.09 | 0.56 | 0.03 |
| Nateglinide | -0.03 | -0.06 | -0.01 |
Blood samples were collected for measurement of GSA prior to (fasting) the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. GSA was assayed at a central laboratory. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | Percentage (Mean) |
|---|---|
| Nateglinide 120 mg | -1.2 |
| Acarbose 50 mg | -1.2 |
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The peak postprandial glucose values were used in the calculation of change from Baseline at Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | mmol/L (Mean) |
|---|---|
| Nateglinide 120 mg | -2.350 |
| Acarbose 50 mg | -3.129 |
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | mmol*min/L (Mean) |
|---|---|
| Nateglinide 120 mg | -217.628 |
| Acarbose 50 mg | -278.447 |
Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. PPGE was defined as the mean difference between the preprandial glucose value and the postprandial glucose value measured at 2 hours in a standardized meal test. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | mmol/L (Mean) |
|---|---|
| Nateglinide 120 mg | -1.775 |
| Acarbose 50 mg | -2.434 |
Blood samples were collected for measurement of FFA prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. FFA was assayed at a central laboratory. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | mmol/L (Mean) | ||||
|---|---|---|---|---|---|
| Fasting, N=73, 75 | 30 minutes, N=73, 75 | 60 minutes, N=72, 75 | 90 minutes, N=72, 75 | 120 minutes, N=73, 75 | |
| Acarbose 50 mg | -0.040 | -0.048 | -0.048 | -0.042 | -0.034 |
| Nateglinide 120 mg | -0.048 | -0.112 | -0.224 | -0.109 | -0.099 |
Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Fasting, N=74, 77 | 120 minutes, N=74, 76 | |
| Acarbose 50 mg | -0.039 | 0.003 |
| Nateglinide 120 mg | 0.020 | 0.023 |
Blood samples were collected for measurement of hsCRP prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. hsCRP was assayed at a central laboratory. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Fasting, N=73, 75 | 30 minutes, N=73, 75 | 60 minutes, N=72, 75 | 90 minutes, N=72, 75 | 120 minutes, N=72, 74 | |
| Acarbose 50 mg | 0.080 | 0.024 | 0.071 | 0.077 | 0.074 |
| Nateglinide 120 mg | -0.229 | -0.227 | -0.219 | -0.220 | -0.218 |
Blood samples were collected for measurement of LDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. LDL-C was assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Fasting, N=74, 77 | 120 minutes, N=74, 76 | |
| Acarbose 50 mg | 0.036 | 0.044 |
| Nateglinide 120 mg | 0.036 | -0.000 |
Blood samples were collected for measurement of total cholesterol prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Total cholesterol was assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Fasting, N=74, 77 | 120 minutes, N=74, 76 | |
| Acarbose 50 mg | -0.149 | -0.059 |
| Nateglinide 120 mg | 0.015 | 0.010 |
Blood samples were collected for measurement of triglycerides prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Triglycerides were assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Fasting, N=74, 77 | 120 minutes, N=74, 76 | |
| Acarbose 50 mg | -0.418 | -0.396 |
| Nateglinide 120 mg | -0.010 | 0.026 |
6 reviews available for n(g),n(g')-dimethyl-l-arginine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Huma | 2023 |
Nutritional factors in the prevention and management of coronary artery disease and heart failure.
Topics: Alprostadil; Anti-Inflammatory Agents; Arginine; CD59 Antigens; Coronary Artery Disease; Diabetes Me | 2015 |
Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA).
Topics: Animals; Arginine; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glucose; Glucose Tolerance Test | 2011 |
L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes.
Topics: Animals; Antihypertensive Agents; Arginine; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans | 2011 |
[Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data].
Topics: Adult; Aged; Aged, 80 and over; Animals; Arginine; Arteriosclerosis; Biomarkers; Cardiovascular Dise | 2004 |
Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium.
Topics: Arginine; Biological Factors; Biomarkers; C-Reactive Protein; Cell Differentiation; Cell Proliferati | 2005 |
20 trials available for n(g),n(g')-dimethyl-l-arginine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Topics: Arginine; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Ty | 2022 |
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Topics: Arginine; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Ty | 2022 |
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Topics: Arginine; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Ty | 2022 |
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Topics: Arginine; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Ty | 2022 |
Asymmetric dimethylarginine and soluble inter-cellular adhesion molecule-1 serum levels alteration following ginger supplementation in patients with type 2 diabetes: a randomized double-blind, placebo-controlled clinical trial.
Topics: Adult; Arginine; Biomarkers; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; Fe | 2018 |
Serum Levels of Protein-Bound Methylglyoxal-Derived Hydroimidazolone-1 are Independently Correlated with Asymmetric Dimethylarginine.
Topics: Aged; Arginine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Gly | 2019 |
Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes.
Topics: Aged; Aged, 80 and over; Arginine; Diabetes Mellitus, Type 2; Female; Fibronectins; Glucose Intolera | 2013 |
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.
Topics: Adamantane; Adult; Aged; Arginine; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptidyl-Peptida | 2014 |
Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease.
Topics: Aged; Aged, 80 and over; Arginine; Cell Adhesion Molecules; Coronary Artery Disease; Diabetes Mellit | 2015 |
Reduction in asymmetric dimethylarginine plasma levels by coenzyme Q10 supplementation in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antioxidants; Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Supplements; | 2015 |
Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.
Topics: Adiponectin; Adult; Aged; Arginine; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl | 2016 |
Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes.
Topics: Arginine; Blood Glucose; Blood Vessels; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agen | 2010 |
Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus.
Topics: Arginine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Thiocti | 2010 |
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus.
Topics: Acarbose; Aged; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; CD40 Ligand; Diabetes Melli | 2010 |
The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes.
Topics: Academic Medical Centers; Arginine; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Dinop | 2012 |
Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combinati | 2012 |
No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk.
Topics: Adolescent; Adult; Arginine; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Do | 2006 |
Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease.
Topics: Aged; Aged, 80 and over; Arginine; Arterial Occlusive Diseases; Blood Platelets; Blood Pressure; Dia | 2006 |
Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Topics: Acarbose; Arginine; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Fema | 2007 |
Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Topics: Acarbose; Arginine; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Fema | 2007 |
Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Topics: Acarbose; Arginine; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Fema | 2007 |
Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Topics: Acarbose; Arginine; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Fema | 2007 |
Hyperbaric oxygen therapy mediates increased nitric oxide production associated with wound healing: a preliminary study.
Topics: Arginine; Chromatography, High Pressure Liquid; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes | 2007 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pre | 2008 |
Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes.
Topics: Adult; Aged; Arginine; Diabetes Mellitus, Type 2; Dietary Fats; Endothelium, Vascular; Female; Human | 2000 |
Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes.
Topics: Arginine; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; H | 2002 |
66 other studies available for n(g),n(g')-dimethyl-l-arginine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Resveratrol improves diabetic cardiomyopathy by preventing asymmetric dimethylarginine-caused peroxisome proliferator-activated receptor-γ coactivator-1α acetylation.
Topics: Acetylation; Animals; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Myocytes, Cardiac; Perox | 2022 |
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy.
Topics: Amidohydrolases; Diabetes Complications; Diabetes Mellitus, Type 2; Genotype; Haptoglobins; Humans; | 2022 |
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy.
Topics: Amidohydrolases; Diabetes Complications; Diabetes Mellitus, Type 2; Genotype; Haptoglobins; Humans; | 2022 |
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy.
Topics: Amidohydrolases; Diabetes Complications; Diabetes Mellitus, Type 2; Genotype; Haptoglobins; Humans; | 2022 |
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy.
Topics: Amidohydrolases; Diabetes Complications; Diabetes Mellitus, Type 2; Genotype; Haptoglobins; Humans; | 2022 |
Restoration of Adiponectin-Connexin43 Signaling Mitigates Myocardial Inflammation and Dysfunction in Diabetic Female Rats.
Topics: Adiponectin; Animals; Arginine; Connexin 43; Diabetes Mellitus, Experimental; Diabetes Mellitus, Typ | 2020 |
Cardiovascular risk factors and the concentration of asymmetric dimethylarginine.
Topics: Adult; Aged; Arginine; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Middl | 2020 |
ADMA (asymmetric dimethylarginine) and angiogenic potential in patients with type 2 diabetes and prediabetes.
Topics: Adult; Aged; Arginine; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle | 2021 |
Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus.
Topics: Adenosine Diphosphate; Adult; Aged; Arginine; Blood Platelets; Calcium; Case-Control Studies; Chroma | 2020 |
Lack of evidence of the correlation between plasma Asymmetrical Dimethylarginine correlation and IMT in type 2 diabetic patients with chronic vascular complication.
Topics: Adult; Aged; Arginine; Atherosclerosis; Carotid Artery, Internal; Carotid Intima-Media Thickness; Ca | 2021 |
A Cross-Talk between the Erythrocyte L-Arginine/ADMA/Nitric Oxide Metabolic Pathway and the Endothelial Function in Subjects with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Citrulline; Cross-Sectional Studies; Diabetes Mellitus, Ty | 2021 |
HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation.
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Chromatography, High Pressure L | 2017 |
Association of circulatory asymmetric dimethylarginine (ADMA) with diabetic nephropathy in Asian Indians and its causative role in renal cell injury.
Topics: Adult; Albuminuria; Animals; Arginine; Asian People; Biomarkers; Cell Line; Creatinine; Diabetes Mel | 2017 |
Physical activity - related changes in ADMA and vWF levels in patients with type 2 diabetes: A preliminary study.
Topics: Adult; Arginine; Cholesterol, HDL; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Male; Middle | 2017 |
Relation of asymmetrical dimethylarginine levels with renal outcomes in hypertensive patients with and without type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Arginine; Biomarkers; Case-Control Studies; Diabetes Complications; Diabetes Mell | 2018 |
Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension.
Topics: Aged; Arginine; Brazil; C-Reactive Protein; Cardiovascular Diseases; Diabetes Complications; Diabete | 2018 |
Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction.
Topics: Arginine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium; Feces; Female; Gastrointe | 2018 |
Changes in arginine are inversely associated with type 2 diabetes: A case-cohort study in the PREDIMED trial.
Topics: Aged; Aged, 80 and over; Arginine; Case-Control Studies; Citrulline; Cohort Studies; Diabetes Mellit | 2019 |
Urinary sodium-to-potassium ratio and serum asymmetric dimethylarginine levels in patients with type 2 diabetes.
Topics: Adult; Aged, 80 and over; Arginine; Blood Pressure; Carotid Intima-Media Thickness; Cross-Sectional | 2018 |
Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo.
Topics: Adult; Age Factors; Aged; Arginine; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Humans | 2013 |
The value of serum asymmetric dimethylarginine levels for the determination of masked hypertension in patients with diabetes mellitus.
Topics: Adult; Arginine; Biomarkers; Blood Pressure Monitoring, Ambulatory; Chi-Square Distribution; Chromat | 2013 |
Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study.
Topics: Adult; Aged; Angina, Stable; Arginine; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose Intoler | 2013 |
ON NO--the continuing story of nitric oxide, diabetes, and cardiovascular disease.
Topics: Arginine; Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Male; Nitric Oxide | 2013 |
Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes.
Topics: Aged; Arginine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Environme | 2014 |
An assessment of correlation between serum asymmetric dimethylarginine and glycated haemoglobin in patients with type 2 diabetes mellitus.
Topics: Arginine; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorben | 2014 |
Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients.
Topics: Aged; Arginine; Atherosclerosis; Biomarkers; Blood Sedimentation; C-Reactive Protein; Carotid Intima | 2014 |
Involvement of increased endogenous asymmetric dimethylarginine in the hepatic endoplasmic reticulum stress of type 2 diabetic rats.
Topics: Animals; Arginine; Cell Line, Tumor; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Liver; | 2014 |
Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin.
Topics: Aged; Arginine; Aspirin; Biomarkers; Cardiovascular Diseases; Case-Control Studies; CD40 Ligand; Cro | 2014 |
Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
Topics: Aged; Albuminuria; Arginine; Biomarkers; Breath Holding; Cohort Studies; Cross-Sectional Studies; Di | 2015 |
Accelerated onset of senescence of endothelial progenitor cells in patients with type 2 diabetes mellitus: role of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine.
Topics: Amidohydrolases; Arginine; Cellular Senescence; Diabetes Mellitus, Type 2; Endothelial Progenitor Ce | 2015 |
Asymmetric dimethylarginine is negatively correlated with hyperglycemia in children.
Topics: Adolescent; Arginine; Biomarkers; Body Mass Index; Cardiovascular Diseases; Child; Cross-Sectional S | 2015 |
The relationship between serum asymmetric dimethylarginine levels and subjective sleep quality in normotensive patients with type 2 diabetes mellitus.
Topics: Adult; Arginine; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Chromatography, High | 2015 |
LC-MS/MS for the simultaneous determination of polar endogenous ADMA and CML in plasma and urine from diabetics.
Topics: Arginine; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Diabetic Nephropathies; H | 2015 |
The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes.
Topics: Albuminuria; Apolipoproteins; Apolipoproteins M; Arginine; Biological Transport; Cholesterol, HDL; C | 2015 |
ADMA: a specific biomarker for pathologic progress in diabetic microvascular complications?
Topics: Adult; Aged; Area Under Curve; Arginine; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2 | 2016 |
Serum asymmetric dimethylarginine and arginine levels predict microvascular and macrovascular complications in type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Arginine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cross- | 2017 |
Asymmetrical dimethyl arginine in type 2 diabetic patients with coronary artery disease.
Topics: Adult; Arginine; Blood Glucose; Case-Control Studies; Coronary Artery Disease; Cross-Sectional Studi | 2016 |
Diabetes-linked transcription factor HNF4α regulates metabolism of endogenous methylarginines and β-aminoisobutyric acid by controlling expression of alanine-glyoxylate aminotransferase 2.
Topics: Aminoisobutyric Acids; Animals; Arginine; Cardiovascular Diseases; Cell Line; Diabetes Mellitus, Typ | 2016 |
Plasma levels of asymmetric dimethylarginine in premature neonates: its possible involvement in developmental programming of chronic diseases.
Topics: Arginine; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Female; Humans; Infan | 2009 |
Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Arginine; Biomarkers; Cohort Studies; Cross-Sectional Studies; Diabetes Me | 2009 |
Relationship between cerebral arterial pulsatility and carotid intima media thickness in diabetic and non-diabetic patients with non-alcoholic fatty liver disease.
Topics: Aged; Arginine; Basilar Artery; Carotid Arteries; Diabetes Mellitus, Type 2; Fatty Liver; Female; Hu | 2009 |
Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase.
Topics: Animals; Aorta, Thoracic; Arginine; Cattle; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, E | 2010 |
Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes.
Topics: Aged; Amidohydrolases; Arginine; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Geno | 2010 |
ADMA is a correlate of insulin resistance in early-stage diabetes independent of hs-CRP and body adiposity.
Topics: Adiposity; Adult; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Case-Control Studies; Cho | 2010 |
Relationships between dimethylarginine and the presence of vertebral fractures in type 2 diabetes mellitus.
Topics: Adult; Aged; Arginine; Bone Density; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Hum | 2010 |
Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus.
Topics: Adult; Arginine; Diabetes Mellitus, Type 2; Endothelium; Female; Hexosaminidases; Humans; Male; Midd | 2010 |
Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Arginine; Asian People; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, T | 2011 |
The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study.
Topics: Aged; Amidohydrolases; Analysis of Variance; Arginine; Biomarkers; Blood Glucose; Cardiovascular Dis | 2011 |
Quantitation of L-arginine and asymmetric dimethylarginine in human plasma by LC-selective ion mode-MS for Type 2 diabetes mellitus study.
Topics: Adult; Aged; Arginine; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Female; Huma | 2011 |
Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot.
Topics: Aged; Arginine; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Foot; Diabetic Neuropathies; Glycate | 2011 |
Changes of skin temperature of parts of the body and serum asymmetric dimethylarginine (ADMA) in type-2 diabetes mellitus Indian patients.
Topics: Adult; Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Indi | 2011 |
The dual behavior of heat shock protein 70 and asymmetric dimethylarginine in relation to serum CRP levels in type 2 diabetes.
Topics: Adult; Arginine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitu | 2012 |
Relationship between plasma asymmetric dimethylarginine level and autonomic dysfunction in diabetic patients.
Topics: Administration, Oral; Arginine; Autonomic Nervous System Diseases; Case-Control Studies; Diabetes Me | 2012 |
Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects.
Topics: Aged; Amidohydrolases; Arginine; Case-Control Studies; Diabetes Complications; Diabetes Mellitus, Ty | 2013 |
Asymmetric dimethylarginine and carotid atherosclerosis in Type 2 diabetes mellitus.
Topics: Adult; Aged; Arginine; Carotid Artery Diseases; Case-Control Studies; Diabetes Complications; Diabet | 2012 |
ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis.
Topics: Adult; Aged; Amidohydrolases; Arginine; Cross-Sectional Studies; Czech Republic; Diabetes Mellitus, | 2012 |
Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patients.
Topics: Arginine; Blood Pressure; Case-Control Studies; Diabetes Complications; Diabetes Mellitus, Type 2; E | 2012 |
Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Arginine; Cross-Over Studies; Diabetes Mellitus, Typ | 2002 |
Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy.
Topics: Aged; Arginine; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Typ | 2003 |
Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes.
Topics: Adult; Aged; Animals; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; | 2005 |
Serum asymmetric dimethylarginine as a marker of coronary microcirculation in patients with non-insulin dependent diabetes mellitus: correlation with coronary flow reserve.
Topics: Aged; Arginine; Biomarkers; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Diab | 2005 |
Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes.
Topics: Aged; Arginine; Arterial Occlusive Diseases; Biomarkers; Chromatography, High Pressure Liquid; Cross | 2006 |
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ar | 2005 |
Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synt
Topics: Arginine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Humans; H | 2006 |
Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes.
Topics: Aged; Arginine; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Midd | 2007 |
Soluble RAGE in type 2 diabetes: association with oxidative stress.
Topics: Arginine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dinoprost; Enzy | 2007 |
Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes.
Topics: Adult; Arginine; Body Mass Index; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diabetic Angiopa | 2007 |
Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Arginine; Coronary Circulation; Diabetes Mellitus, T | 2009 |
Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus.
Topics: Arginine; Blood Glucose; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Enzyme Inhibi | 2001 |